在巴西免疫规划中引入MenB疫苗(Bexsero)的健康影响与成本效果
本研究采用队列模型,比较巴西常规接种Bexsero疫苗与不接种两种策略。假设3剂次接种、每剂90雷亚尔、疫苗效力82.0%、接种率90.0%,估计可预防1,527例MenB病例、避免78例死亡,但每避免一个DALY的ICER为372,256雷亚尔,接种规划不太可能具有成本效果。
要点
- 在3剂次、每剂90雷亚尔、效力82.0%、接种率90.0%的假设下,可预防1,527例MenB病例并避免78例死亡。
- ICER为每避免一个DALY 372,256雷亚尔,接种规划不太可能具有成本效果。
核心结论
- 在假设的接种方案与参数下,巴西引入Bexsero疫苗至免疫规划不太可能具有成本效果。
研究设计与样本
- 采用队列模型,比较常规接种MenB疫苗与不接种两种策略。
- 流行病学与成本估计来自巴西卫生信息系统。
- 假设3剂次接种方案、每剂疫苗90雷亚尔、MenB疫苗效力82.0%、接种率90.0%。
主要发现
- 估计可预防1,527例MenB病例,避免78例死亡。
- 每避免一个DALY的ICER为372,256雷亚尔。
关键数值与推荐
- 疫苗效力82.0%,接种率90.0%,每剂90雷亚尔,3剂次方案。
- ICER为每避免一个DALY 372,256雷亚尔。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Invasive meningococcal disease (IMD) is associated with a high mortality and severe sequelae. The aim of the present study was to evaluate the potential cost-effectiveness of the Bexsero vaccine in Brazil. We used a cohort model to compare routine vaccination against MenB disease with no vaccination. Epidemiological and cost estimates were obtained from the Brazilian Health Information System. The cost per disability-adjusted life year (DALY) averted and incremental cost-effectiveness ratio (ICER) was estimated assuming a 3-dose vaccination schedule, at R$90 (£ 20.50) per vaccine dose, 82.0% vaccine efficacy against MenB disease and a vaccine uptake of 90.0%. We estimated that 1,527 MenB cases would be prevented and 78 deaths averted. This strategy would cost R$ 762,381, 000 (£ 174,059,503) with a R$ 4,364,280 (£ 996,410) reduction in disease treatment costs. However, at an ICER of 372,256 (£ 84,990) per DALY averted, a vaccination programme is unlikely to be cost-effective.
引用
- Moura Silveira M, McBride AJA, Trotter CL, et al. Health impact and cost-effectiveness of introducing the vaccine (Bexsero) against MenB disease into the Brazilian immunization programme. Vaccine. 2019. PMID: 31570182. doi:10.1016/j.vaccine.2019.09.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。